Entity
Description
  • Value proposition

    CeleScreen develops an innovative technology for the rapid screening of xenobiotics toxicity by means of Caenorhabditis elegans, a <1mm nematode, long-known model for human metabolism. It is a unique solution for systemic toxicity, reprotoxicity, teratogenicity, while avoiding vertebrate testing. Primary targets are in the cosmetics industry to face REACH demands. Celescreen has recently launched collaborative projects incorporating C. elegans and in silico approaches for drug development in human health.

    Incorporated in 2015, based at Hôpital Lariboisière in Paris, CeleScreen is a licensee of Assistance Publique - Hôpitaux de Paris (AP-HP), a major player in human health with >20,000 medical doctors.

    toxicology, systemic toxicity, reprotoxicity, teratogenicity, REACH, drug design, lead optimization, and C. elegans

  • Original language

    CeleScreen develops an innovative technology for the rapid screening of xenobiotics toxicity by means of Caenorhabditis elegans, a <1mm nematode, long-known model for human metabolism. It is a unique solution for systemic toxicity, reprotoxicity, teratogenicity, while avoiding vertebrate testing. Primary targets are in the cosmetics industry to face REACH demands. Celescreen has recently launched collaborative projects incorporating C. elegans and in silico approaches for drug development in human health.

    Incorporated in 2015, based at Hôpital Lariboisière in Paris, CeleScreen is a licensee of Assistance Publique - Hôpitaux de Paris (AP-HP), a major player in human health with >20,000 medical doctors.

  • CeleScreen - Innovative method of assessing toxicity in systemic organism

    Celescreen develops an innovative process of assessing toxicity in systemic organism using an invertebrate, the worm Caenorhabditis elegans

  • https://www.celescreen.com/
Corporate interactions BETA
Corporate TypeTweets Articles
Slush
Slush
Non-profit Organizations
Slush
Non-profit Organizations
Other

13 Nov 2015


Sanofi
Sanofi
Pharmaceutical, Pharmaceutical Manufacturing
Sanofi
Pharmaceutical, Pharmaceutical Manufacturing
Other

3 Dec 2015


50 Partners
50 Partners
Startup accelerator & VC, Venture Capital & Private Equity
50 Partners
Startup accelerator & VC, Venture Capital & Private Equity
Other

20 May 2015


Bpifrance
Bpifrance
Bank, Banking
Bpifrance
Bank, Banking
Not capitalistic
Not partnership
Event

7 Jul 2016


Start in Saclay
Start in Saclay
Startup accelerator & VC, Civic and Social Organizations
Start in Saclay
Startup accelerator & VC, Civic and Social Organizations
Not capitalistic
Partnership
Not event

15 Jan 2016


Business France
Business France
National and local authorities, Government Administration
Business France
National and local authorities, Government Administration
Not capitalistic
Not partnership
Event

2 Nov 2015


Johnson & Johnson
Johnson & Johnson
Pharmaceutical, Hospitals and Health Care
Johnson & Johnson
Pharmaceutical, Hospitals and Health Care
Other

28 Sep 2015


Agoranov
Agoranov
Startup accelerator & VC, Technology, Information and Internet
Agoranov
Startup accelerator & VC, Technology, Information and Internet
Not capitalistic
Partnership
Event

7 Jul 2016


Paris&Co
Paris&Co
Startup accelerator & VC, Civic and Social Organizations
Paris&Co
Startup accelerator & VC, Civic and Social Organizations
Not capitalistic
Not partnership
Event

3 Dec 2015


L'Express
L'Express
Media, Newspaper Publishing
L'Express
Media, Newspaper Publishing
Not capitalistic
Not partnership
Event

30 Nov 2015


Similar entities
Loading...
Loading...
Social network dynamics